Assessing long-term maintenance of efficacy with tralokinumab monotherapy in patients with moderate-to-severe atopic dermatitis: combined results from two Phase 3, randomized, double-blind, placebo-controlled trials (ECZTRA 1 and 2)

Andrew Blauvelt,1 Andreas Wollenberg,2 Andrew Pink,3 Ketty Peris,4 April Armstrong,5 Lynda Spelman,6 Hidehisa Saeki,7 Charles Lynde,8 Pedro Herranz,9 Sebastien Barbarot,10 Eric Simpson11

1Oregon Medical Research Center, Portland, OR, USA; 2Department of Dermatology and Allergology, Ludwig-Maximilian University of Munich, Munich, Germany; 3St. John’s Institute of Dermatology, Guy’s and St. Thomas’ Hospitals, London, UK; 4Dermatology, Catholic University and Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy; 5Department of Dermatology, Keck School of Medicine at the University of Southern California, Los Angeles, CA, USA; 6Veracity Clinical Research, Brisbane, Queensland, Australia, and Probit Medical Research, Woolloongabba, Queensland, Australia; 7Department of Dermatology, Nippon Medical School, Tokyo, Japan; 8Lynde Dermatology, Probity Medical Research, Markham, Ontario, Canada, and Department of Medicine, University of Toronto, Ontario, Canada; 9Department of Dermatology, Hospital Universitario La Paz, Madrid, Spain; 10Centre Hospitalier Universitaire de Nantes, Nantes, France; 11Department of Dermatology, Oregon Health & Science University, Portland, OR, USA

Background: Tralokinumab is a fully human, high-affinity monoclonal antibody that specifically neutralizes interleukin-13, a key driver of skin inflammation and barrier dysfunction in atopic dermatitis (Bieber T, et al. Allergy. 2020;75:54-62; Popovic B et al. J Mol Biol. 2017;429:208-219). In two phase 3 trials, ECZTRA 1 and 2, tralokinumab monotherapy was superior to placebo for all primary and secondary endpoints at week 16 in adults with moderate-to-severe atopic dermatitis (Wollenberg A, et al. Br J Dermatol. 2021;184:437-449). We evaluated the maintenance of response beyond 16 weeks of tralokinumab monotherapy in patients who were initial responders; and assessed whether reduced dosing frequency of tralokinumab from q2w to q4w had an impact on maintenance of efficacy.

Methods: High-responding patients achieving Investigator’s Global Assessment (IGA) 0/1 or Eczema Area and Severity Index (EASI)-75 at week 16 on tralokinumab q2w were rerandomized in the maintenance phase 2:2:1 to tralokinumab q2w, q4w, or placebo for 36 weeks. A prespecified, pooled analysis assessed maintenance of response (IGA 0/1 or EASI-75) at week 52. Rescue medication use, including topical corticosteroids, was considered non-response. Post hoc analysis of time to relapse (transfer to open-label period, rescue medication, or treatment discontinuation) was conducted.

Results: A large proportion of high-responding patients (n=337) continuing tralokinumab q2w or q4w maintained response without any rescue medication, including topical corticosteroids, at week 52. With q2w, 56.2% maintained IGA 0/1 or EASI-75 (difference=26.3% vs placebo; P<0.001) at week 52. With q4w, 50.0% maintained IGA 0/1 or EASI-75 (difference=20.7% vs placebo; P=0.003). Time to relapse based on IGA 0/1 and EASI-75 was prolonged with tralokinumab vs placebo (q2w, P=0.004 and q4w, P=0.14; q2w, P=0.002 and q4w, P=0.044, respectively). Overall, adverse event frequency was similar for tralokinumab q2w (73%), q4w (66%), and placebo (70%).

Conclusions: In patients with moderate-to-severe atopic dermatitis treated with tralokinumab monotherapy, the initial response to tralokinumab was maintained at high levels at week 52 without topical corticosteroid use and was well tolerated. Step-down to q4w dosing may be an option for some patients.

Funding Source: The ECZTRA 1 and 2 studies were sponsored by LEO Pharma A/S, Ballerup, Denmark.